This week, we're sharing more from the 2023 joint ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) and ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) annual meeting.
What if we could identify MS before anyone experienced any of the typical clinical symptoms? Would treating that person with a high-efficacy disease-modifying therapy prevent the clinical symptoms of MS from even developing? These are the questions that make the study of the MS prodrome so fascinating and important. At the joint ECTRIMS-ACTRIMS meeting, I met up with one of the foremost experts on the prodromal phase of MS, Dr. Helen Tremlett, who shared an update on what she's continuing to learn about the MS prodrome.
We'll also tell you about Dr. Jeffrey Huang's work in developing an experimental drug that may stop MS progression and stimulate remyelination.
We're sharing a report from Deloitte that analyzes the economic impact of the pandemic gap for people living with MS in Canada.
We'll tell you about the results of a study that show lower-efficacy disease-modifying therapies can lead to faster disability accumulation.
You'll hear about the work being done to deliver Ocrevus in a subcutaneous injection.
And we'll tell you what happened that caused a study focused on stopping your DMT if your MS was stable to be called off.
I had the good fortune of speaking with several research presenters at the joint ECTRIMS-ACTRIMS meeting, and I'll be releasing those bonus ECTRIMS Extra Conversations all week long. It's an opportunity for you to listen in to my conversations with some of the top MS research and clinical experts in the world. Be sure to look for these conversations throughout this week!
We have a lot to talk about! Are you ready for RealTalk MS??!
This Week: More from the largest MS research conference in the world :22
Don't miss ECTRIMS Extra Conversations all week long!
Georgetown University researchers develop a drug that may stop MS progression and stimulate remyelination 1:20
The cost of the pandemic gap for people living with MS in Canada 3:10
Study shows that lower-efficacy DMTs can lead to faster disability accumulation 7:12
Clinical trial demonstrates that subcutaneous formulation of Ocrevus is safe and effective 10:47
Your MS stable, no relapses for at least 5 years. Can you stop your DMT? 12:33
Dr. Helen Tremlett explains how understanding the MS prodrome can change the future of MS treatment 15:49
Share this episode 21:26
Have you downloaded the free RealTalk MS app? 21:47
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/321
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
REPORT: The Socioeconomic Cost of, and Impact of, COVID-19 on Multiple Sclerosis in Canada
ECTRIMS PRESENTATION: Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis: Results of the Phase 1b Dose-Finding OCARINA 1 Study
ECTRIMS PRESENTATION: Discontinuation of First-Line Disease-Modifying Therapy in Stable MS (DOT-MS): An Early-Terminated Multicenter Randomized Controlled Trial
Join the RealTalk MS Facebook Group
Download the RealTalk MS App for iOS Devices
Download the RealTalk MS App for Android Devices
Give RealTalk MS a rating and review
RealTalk MS Episode 321
Guest: Dr. Helen Tremlett